

# Retinitis Pigmentosa - Pipeline Insight, 2021

<https://marketpublishers.com/r/RE988738EF5EN.html>

Date: May 2021

Pages: 80

Price: US\$ 2,000.00 (Single User License)

ID: RE988738EF5EN

## Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Retinitis Pigmentosa - Pipeline Insight, 2021," report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Retinitis Pigmentosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Retinitis Pigmentosa Understanding

#### Retinitis Pigmentosa: Overview

Retinitis pigmentosa (RP) is an umbrella term for a group of hereditary progressive retinal disorders that cause progressive degeneration of the retina. The disease is inherited as autosomal recessive, autosomal dominant or X-linked recessive traits. Signs of retinitis pigmentosa usually appear during childhood or adolescence. Common symptoms include difficulty seeing at night and a loss of side (peripheral) vision. RP is diagnosed by electroretinography (ERG), visual field testing, and retinal imaging, fundus auto-fluorescence (FAF) and genetic testing. Currently, there is no therapy that stops the evolution of pigmentary retinopathies or restores the vision. Management of retinitis pigmentosa includes dietary supplements, ozone therapy, surgery etc. Gene therapy based treatments are under research focus for the treatment of Retinitis pigmentosa.

'Retinitis Pigmentosa - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Retinitis Pigmentosa pipeline landscape is provided which includes the disease overview and Retinitis Pigmentosa treatment guidelines. The assessment part of the report embraces, in depth Retinitis Pigmentosa commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Retinitis Pigmentosa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Retinitis Pigmentosa R&D. The therapies under development are focused on novel approaches to treat/improve Retinitis Pigmentosa.

## Retinitis Pigmentosa Emerging Drugs Chapters

This segment of the Retinitis Pigmentosa report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Retinitis Pigmentosa Emerging Drugs

### BIIB-112: Biogen

BIIB-112 (formerly called NSR-RPGR) consists of a standard AAV8 vector carrying a codon optimized RPGR gene. BIIB112 is in phase II clinical studies for X-linked retinitis pigmentosa treatment. In September 2018, NSR-RPGR was granted orphan drug designation for the treatment of inherited retinal dystrophies due to defects in the RPGR gene from the U.S. Food and Drug Administration.

### QR 1123 (formerly ISIS RHO 2.5Rx): Ionis Pharmaceuticals

QR 1123 (formerly ISIS RHO 2.5Rx) is an antisense oligonucleotide, designed to specifically target the mutant P23H messenger ribonucleic acid (mRNA) in order to reduce the expression of the P23H protein selectively, while preserving expression of the wild type (WT) rhodopsin (RHO) protein. The therapy is currently in Phase II clinical evaluation for the treatment of Retinitis Pigmentosa. In November 2019, ProQR Therapeutics announced that it received Orphan Drug designation (ODD) from the Food and Drug Administration (FDA) for QR-1123. QR-1123 was in-licensed from Ionis Pharmaceuticals in 2018. QR-1123 has also received Fast Track designation from the FDA.

Further product details are provided in the report

### Retinitis Pigmentosa: Therapeutic Assessment

This segment of the report provides insights about the different Retinitis Pigmentosa drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Retinitis Pigmentosa

There are approx. 45+ key companies which are developing the therapies for Retinitis Pigmentosa. The companies which have their Retinitis Pigmentosa drug candidates in the most advanced stage, i.e. Phase II include, Biogen.

#### Phases

DelveInsight's report covers around 45+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Retinitis Pigmentosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### Retinitis Pigmentosa: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Retinitis Pigmentosa therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Retinitis Pigmentosa drugs.

### Retinitis Pigmentosa Report Insights

Retinitis Pigmentosa Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

### Retinitis Pigmentosa Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Retinitis Pigmentosa drugs?

How many Retinitis Pigmentosa drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Retinitis Pigmentosa?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Retinitis Pigmentosa therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Retinitis Pigmentosa and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Biogen

Neurotech

Ionis Pharmaceuticals

Novartis Pharmaceuticals

Nacuity Pharmaceuticals

ReNeuron

ID Pharma

Allegro Ophthalmics

SparingVision

Editas Medicine

OiDE OptoEye

## Key Products

BIIB-112

NT 501

QR 1123 (formerly ISIS RHO 2.5Rx)

CPK 850

N-acetylcysteine-amide

ReN 003

DVC1-0401

Risuteganib

SPVN 06

SPVN 20

LCA10 program

GtCCR4 gene therapy

## Contents

Introduction

Executive Summary

Retinitis Pigmentosa: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Retinitis Pigmentosa – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Retinitis Pigmentosa companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Retinitis Pigmentosa Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

BIIB-112: Biogen

Product Description

Research and Development

Product Development Activities



Drug profiles in the detailed report  
Early Stage Products (Phase I)  
    Comparative Analysis  
N-acetylcysteine-amide: Nacuity Pharmaceuticals  
    Product Description  
    Research and Development  
    Product Development Activities  
Drug profiles in the detailed report  
Preclinical and Discovery Stage Products  
    Comparative Analysis  
SPVN 06: SparingVision  
    Product Description  
    Research and Development  
    Product Development Activities  
Drug profiles in the detailed report  
Inactive Products  
    Comparative Analysis  
Retinitis Pigmentosa Key Companies  
Retinitis Pigmentosa Key Products  
Retinitis Pigmentosa- Unmet Needs  
Retinitis Pigmentosa- Market Drivers and Barriers  
Retinitis Pigmentosa- Future Perspectives and Conclusion  
Retinitis Pigmentosa Analyst Views  
Retinitis Pigmentosa Key Companies  
Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Retinitis Pigmentosa

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Retinitis Pigmentosa

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Retinitis Pigmentosa - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/RE988738EF5EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RE988738EF5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970